| Identification | Back Directory | [Name]
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione | [CAS]
2088771-61-1 | [Synonyms]
Impurity FP-B
Sitagliptin-17
Sitagliptin Impurity 20
Sitagliptin Impurity FP-B
Sitagliptin FP Impurity B
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)
Sitagliptin FP Impurity B/ Sitagliptin Triazecine Analog
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione
1,2,4-Triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione, 6,7,10,11-tetrahydro-3-(trifluoromethyl)-10-[(2,4,5-trifluorophenyl)methyl]-, (10R)-
(10R)?- 6,?7,?10,?11-?Tetrahydro-?3-?(trifluoromethyl)?-?10-?[(2,?4,?5-?trifluorophenyl)?methyl]?-1,?2,?4-?triazolo[3,?4-?c]?[1,?4,?7]?triazecine-?8,?12(5H,?9H)?-?dione
Sitagliptin impurity 6/Sitagliptin FP Impurity B/Sitagliptin Triazecine Analog/10-(2,4,5-Trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro [1,2,4] triazolo [3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione | [Molecular Formula]
C16H13F6N5O2 | [MDL Number]
MFCD32669788 | [MOL File]
2088771-61-1.mol | [Molecular Weight]
421.3 |
| Chemical Properties | Back Directory | [Melting point ]
>189°C (dec.) | [density ]
1.67±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.02±0.40(Predicted) | [color ]
White to Off-White | [InChI]
InChI=1S/C16H13F6N5O2/c17-9-6-11(19)10(18)4-7(9)3-8-5-12(28)23-1-2-27-13(14(29)24-8)25-26-15(27)16(20,21)22/h4,6,8H,1-3,5H2,(H,23,28)(H,24,29)/t8-/m1/s1 | [InChIKey]
CJUCSNDPMOGZTM-MRVPVSSYSA-N | [SMILES]
N1[C@H](CC2=CC(F)=C(F)C=C2F)CC(=O)NCCN2C(C(F)(F)F)=NN=C2C1=O |
| Hazard Information | Back Directory | [Uses]
(10R)-Sitagliptin Triazecine Analog is related to the family of Sitagliptin compounds which has recently been approved for the therapy of type II diabetes. |
|
|